Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ling Dai

Showing results (301-310 of 385) with videos related to

Pageof 39
Sort By:
Future Oncology (London, England)|February 19, 2016
Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patientsGuangming Tian, Xinliang Zhao, Jun Nie, et al.
Talanta|May 18, 2023
Temperature-boosted PAM-less activation of CRISPR-Cas12a combined with selective inhibitors enhances detection of SNVs with VAFs below 0.01Kena Chen, Ling Dai, Jie Zhao, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 11, 2021
Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data studyYa-Nan Jin, Ji-Jin Yao, Ya-Fei You, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 27, 2013
Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2Xiao-qin Zhao, Chun-ling Dai, Shinobu Ohnuma, et al.
Thoracic Cancer|June 12, 2019
Salvage treatment with anlotinib for advanced non-small cell lung cancerDi Wu, Jun Nie, Ling Dai, et al.
Frontiers in Oncology|March 22, 2021
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From ChinaXiaoling Chen, Jun Nie, Ling Dai, et al.
Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica|September 1, 2021
[Analysis of status quo of outcome indicators of randomized controlled trials in treatment of acute ischemic stroke with acupuncture in recent three years]Ling-Ling Dai, Zhen-Min Xu, Xiao Liang, et al.
International Journal of Cancer|June 20, 2020
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancerDi Wu, Jun Nie, Weiheng Hu, et al.
ACS Applied Materials & Interfaces|May 21, 2015
Rational Design and Facial Synthesis of Li3V2(PO4)3@C Nanocomposites Using Carbon with Different Dimensions for Ultrahigh-Rate Lithium-Ion BatteriesWen-feng Mao, Yan-bao Fu, Hui Zhao, et al.
Annals of Palliative Medicine|August 6, 2021
Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort studyXiaoling Chen, Jun Nie, Ling Dai, et al.
Pageof 39

Showing results (301-310 of 385) with videos related to

Sort By:
Pageof 39
Future Oncology (London, England)|February 19, 2016
Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patientsGuangming Tian, Xinliang Zhao, Jun Nie, et al.
Talanta|May 18, 2023
Temperature-boosted PAM-less activation of CRISPR-Cas12a combined with selective inhibitors enhances detection of SNVs with VAFs below 0.01Kena Chen, Ling Dai, Jie Zhao, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 11, 2021
Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data studyYa-Nan Jin, Ji-Jin Yao, Ya-Fei You, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 27, 2013
Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2Xiao-qin Zhao, Chun-ling Dai, Shinobu Ohnuma, et al.
Thoracic Cancer|June 12, 2019
Salvage treatment with anlotinib for advanced non-small cell lung cancerDi Wu, Jun Nie, Ling Dai, et al.
Frontiers in Oncology|March 22, 2021
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From ChinaXiaoling Chen, Jun Nie, Ling Dai, et al.
Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica|September 1, 2021
[Analysis of status quo of outcome indicators of randomized controlled trials in treatment of acute ischemic stroke with acupuncture in recent three years]Ling-Ling Dai, Zhen-Min Xu, Xiao Liang, et al.
International Journal of Cancer|June 20, 2020
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancerDi Wu, Jun Nie, Weiheng Hu, et al.
ACS Applied Materials & Interfaces|May 21, 2015
Rational Design and Facial Synthesis of Li3V2(PO4)3@C Nanocomposites Using Carbon with Different Dimensions for Ultrahigh-Rate Lithium-Ion BatteriesWen-feng Mao, Yan-bao Fu, Hui Zhao, et al.
Annals of Palliative Medicine|August 6, 2021
Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort studyXiaoling Chen, Jun Nie, Ling Dai, et al.
Pageof 39